Treatment Options and Personalized Care
At a Glance
Leptomeningeal melanoma treatment is personalized according to BRAF mutation status, how quickly symptoms are worsening, overall health, and control of melanoma elsewhere. Options may include immunotherapy, targeted therapy, radiation, clinical trials, and supportive care.
Deciding on a treatment plan for leptomeningeal disease (LMD) requires a specialized, multidisciplinary approach. Because melanoma cells are moving through the fluid around your brain and spine, your care team will likely include neuro-oncologists, radiation oncologists, and your primary melanoma oncologist [1][2]. While LMD is a serious complication, modern therapies have moved us beyond “one-size-fits-all” care toward personalized strategies based on your tumor’s genetics and how you are feeling [3].
Systemic Therapies: The Mainstay of Care
Most treatments for LMD are “systemic,” meaning they travel through your entire body. The choice often depends on how quickly your symptoms are progressing and whether your melanoma has a specific genetic mutation called BRAF V600 [4].
Immunotherapy (Ipilimumab + Nivolumab)
For many patients, the combination of two immunotherapy drugs—ipilimumab and nivolumab—may be considered as a starting point, especially if the disease is not causing immediate, severe symptoms [4].
- The Goal: These drugs “unleash” your immune system to find and kill cancer cells.
- The Benefit: Immunotherapy is known for its potential to create durable responses, meaning the cancer may stay under control for a longer period compared to other treatments [5].
- The Trade-off: It can take weeks or even months for the immune system to fully ramp up. If your symptoms are worsening rapidly, your doctor might choose a faster-acting option first [6]. Safety Warning: Combination immunotherapy can cause serious or delayed immune-related inflammation affecting the bowel, lungs, liver, hormone glands, heart, skin, or nervous system. Contact your oncology team immediately for new or severe symptoms.
Targeted Therapy (BRAF and MEK Inhibitors)
About 50% to 65% of melanomas have a BRAF mutation [7]. If your tumor has this mutation, your doctor may prescribe targeted pills (such as dabrafenib/trametinib or encorafenib/binimetinib) [4].
- The Goal: These drugs block the specific “engine” driving the cancer’s growth.
- The Benefit: Targeted therapy often works very quickly, sometimes providing symptom relief within days [6]. This makes it a vital tool if the disease is progressing fast or causing significant pain or weakness [4].
- The Trade-off: While effective, the cancer often eventually finds a way to “bypass” these drugs, so the responses may not last as long as those from immunotherapy [8]. Safety Warning: These therapies can cause high fevers, rash, diarrhea, eye problems, and heart or liver issues, requiring close monitoring.
The Emerging Role of “Intrathecal” Therapy
Because the blood-brain barrier can block some drugs from reaching the fluid where LMD lives, researchers are exploring intrathecal (IT) therapy—delivering medication directly into the cerebrospinal fluid [9].
IT Nivolumab is an investigational approach. Instead of receiving the drug only through an IV, it is injected directly into the fluid via a lumbar puncture or a specialized port in the head called an Ommaya reservoir [10].
- Current Evidence: Early trials have shown that this approach is feasible. In one small, selected, nonrandomized study, patients receiving IT nivolumab lived for a median of about 5 months, and some saw much longer benefits, but this does not establish it as a standard of care [10].
- Availability: This is considered an “investigational” treatment. You may need to join a clinical trial or be at a specialized academic center to access it [11][12]. It carries procedure risks and requires specialist assessment of CSF flow before starting.
Radiation: Targeting the “Bulky” Disease
Radiation is used to treat specific areas of the brain or spine where cancer cells have clumped together into “nodules” or are blocking the flow of fluid [13].
- Focal Radiation: This is used to treat one specific spot—for example, a spot on the spine causing leg weakness or a spot at the base of the brain affecting your vision [14]. It is highly effective at relieving localized symptoms [13].
- Whole Brain Radiation Therapy (WBRT): Its role depends heavily on the distribution of your disease, symptoms, and prior treatments. It is used selectively because it can cause significant fatigue and memory issues [14][15].
- Proton Craniospinal Irradiation (CSI): This is a newer, more precise form of radiation that treats the entire fluid-filled space from the top of the brain to the base of the spine [16]. By using protons instead of traditional X-rays, doctors can spare healthy organs (like the heart and lungs) from unnecessary radiation [17]. While promising, it is not risk-free and is supported by selected studies rather than definitive melanoma-specific evidence [18].
Choosing the Best Path
Your care team will look at several factors to help you choose the right sequence of treatments:
- Performance Status: This is a medical term for how well you can perform daily tasks. Patients who are still active and have fewer neurological symptoms often have more treatment options available to them [15][16].
- Systemic Control: If the melanoma in the rest of your body (lungs, liver, etc.) is well-controlled, your doctors can focus more aggressively on the LMD [15].
- Clinical Trials: Because LMD is a complex condition, clinical trials are often an important option when available, offering access to new drugs and combinations [2].
Treatment for LMD is about disease-directed care working hand-in-hand with palliative and supportive care. Palliative care is not giving up; it is essential for managing pain, nausea, and mood while you receive active treatment [1].
Common questions in this guide
What treatment options are available for leptomeningeal melanoma?
How is immunotherapy different from targeted therapy for leptomeningeal disease?
Is intrathecal nivolumab a standard treatment for leptomeningeal melanoma?
When is radiation used for leptomeningeal melanoma?
What factors determine a personalized treatment plan for leptomeningeal melanoma?
Which treatment side effects should prompt an urgent call to the oncology team?
Get notified when new evidence is published on leptomeningeal melanoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (18)
- 1
Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions.
Wilcox JA, Chukwueke UN, Ahn MJ, et al.
Neuro-oncology 2024; (26(10)):1781-1804 doi:10.1093/neuonc/noae103.
PMID: 38902944 - 2
Leptomeningeal disease in melanoma: An update on the developments in pathophysiology and clinical care.
Smalley I, Boire A, Brastianos P, et al.
Pigment cell & melanoma research 2024; (37(1)):51-67 doi:10.1111/pcmr.13116.
PMID: 37622466 - 3
Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors.
Le Rhun E, Devos P, Weller J, et al.
Neuro-oncology 2021; (23(7)):1100-1112 doi:10.1093/neuonc/noaa298.
PMID: 33367859 - 4
Melanoma brain metastases - Interdisciplinary management recommendations 2020.
Gutzmer R, Vordermark D, Hassel JC, et al.
Cancer treatment reviews 2020; (89()):102083 doi:10.1016/j.ctrv.2020.102083.
PMID: 32736188 - 5
Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis.
Brastianos PK, Strickland MR, Lee EQ, et al.
Nature communications 2021; (12(1)):5954 doi:10.1038/s41467-021-25859-y.
PMID: 34642329 - 6
Systemic Therapy for Melanoma Brain and Leptomeningeal Metastases.
Sherman WJ, Romiti E, Michaelides L, et al.
Current treatment options in oncology 2023; (24(12)):1962-1977 doi:10.1007/s11864-023-01155-3.
PMID: 38158477 - 7
Leptomeningeal disease from melanoma-Poor prognosis despite new therapeutic modalities.
Chorti E, Kebir S, Ahmed MS, et al.
European journal of cancer (Oxford, England : 1990) 2021; (148()):395-404 doi:10.1016/j.ejca.2021.02.016.
PMID: 33789203 - 8
Survival improvements in patients with melanoma brain metastases and leptomeningeal disease in the modern era: Insights from a nationwide study (2015-2022).
Pedersen S, Johansen EL, Højholt KL, et al.
European journal of cancer (Oxford, England : 1990) 2025; (217()):115253 doi:10.1016/j.ejca.2025.115253.
PMID: 39874911 - 9
Complement Component 3 Adapts the Cerebrospinal Fluid for Leptomeningeal Metastasis.
Boire A, Zou Y, Shieh J, et al.
Cell 2017; (168(6)):1101-1113.e13 doi:10.1016/j.cell.2017.02.025.
PMID: 28283064 - 10
Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.
Glitza Oliva IC, Ferguson SD, Bassett R, et al.
Nature medicine 2023; (29(4)):898-905 doi:10.1038/s41591-022-02170-x.
PMID: 36997799 - 11
Advances in Diagnosis and Treatment for Leptomeningeal Disease in Melanoma.
Piña Y, Yadugiri S, Yeboa DN, et al.
Current oncology reports 2022; (24(1)):43-54 doi:10.1007/s11912-021-01162-3.
PMID: 35059999 - 12
Continuous Intrathecal Infusion of Nivolumab in Advanced Melanoma With Concomitant Leptomeningeal Disease: Efficacy, Safety, and Pharmacokinetics.
Faillot M, Goldwirt L, Jouenne F, et al.
Neurosurgery 2026; (99(4)):882-889 doi:10.1227/neu.0000000000003924.
PMID: 41636506 - 13
An overview of leptomeningeal disease.
Nguyen TK, Nguyen EK, Soliman H
Annals of palliative medicine 2021; (10(1)):909-922 doi:10.21037/apm-20-973.
PMID: 32921068 - 14
How we treat patients with leptomeningeal metastases.
Le Rhun E, Preusser M, van den Bent M, et al.
ESMO open 2019; (4(Suppl 2)):e000507 doi:10.1136/esmoopen-2019-000507.
PMID: 31231573 - 15
Survival and treatment outcomes in patients with leptomeningeal disease from metastatic melanoma.
Saberian C, Milton DR, Simon J, et al.
Neuro-oncology practice 2024; (11(4)):452-463 doi:10.1093/nop/npae026.
PMID: 39006528 - 16
Radiation Therapy in the Management of Leptomeningeal Disease From Solid Tumors.
Barbour AB, Kotecha R, Lazarev S, et al.
Advances in radiation oncology 2024; (9(2)):101377 doi:10.1016/j.adro.2023.101377.
PMID: 38405313 - 17
Survival and hematologic toxicity after whole-brain radiotherapy, photon craniospinal irradiation, and proton craniospinal irradiation for solid-tumor leptomeningeal disease: a systematic review.
Munir M, Sehrawat K, Hassan H, et al.
Journal of neuro-oncology 2026; (179(2)).
PMID: 42667527 - 18
Proton Craniospinal Irradiation with Immunotherapy in Two Patients with Leptomeningeal Disease from Melanoma.
Sener U, Webb M, Breen WG, et al.
Journal of immunotherapy and precision oncology 2024; (7(1)):1-6 doi:10.36401/JIPO-23-20.
PMID: 38327758
This page is for informational purposes only and does not constitute medical advice. Treatment decisions for leptomeningeal melanoma should be made with your neuro-oncology, radiation oncology, and melanoma care teams.